Results 91 to 100 of about 14,209 (224)
Amyloidosis is a heterogeneous group of disorders associated with pathological deposition of amyloid. We can recognize two major categories of amyloidosis: primary (AL) and secondary (AA) type.
Agnieszka Danuta Gaczkowska +2 more
doaj +1 more source
Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis [PDF]
Background: We compared a novel assay for free light chain (FLC) quantitation based on monoclonal antibodies (N-Latex, Siemens, Germany) to the established polyclonal antibody-based assay (Freelite (TM), The Binding Site, UK) in AL ...
Campbell +33 more
core +1 more source
ABSTRACT Proteinuria analysis is necessary to detect the early stages of kidney disease before the estimated glomerular filtration rate deteriorates and to monitor the progression of treated kidney disease. Electrophoresis is often the first orientation test, although this test is time‐consuming and its interpretation may be subjective.
Joris Guyon +8 more
wiley +1 more source
ATTR Variant Amyloidosis in Patients with Dysphagia
Amyloidosis is a rare disease characterized by the accumulation of misfolded extracellular proteins in various organs. Over 30 precursor proteins have been identified that can form amyloid deposits in different parts of the body.
Christina Hui Lee Ng +2 more
doaj +1 more source
Amiloidose renal: classificação de 102 casos consecutivos [PDF]
Amyloidoses are a group of heterogeneous diseases classified according to the nature of their causative amyloid proteins. Commonly, paraffin-embedded tissue is used for the typing of amyloid by immunohistochemistry.
Lobato, L. +8 more
core
Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds [PDF]
PURPOSE: 18F-Florbetapir has been reported to show cardiac uptake in patients with systemic light-chain amyloidosis (AL). This study systematically assessed uptake of 18F-florbetapir in patients with proven systemic amyloidosis at sites outside the heart.
Burniston, M +8 more
core +1 more source
Central nervous system involvement in cardiac amyloidosis: Redefining the heart‐brain axis
Central nervous system involvement in cardiac amyloidosis. Amyloidosis is a systemic disease that can directly affect the central nervous system. Furthermore, the amyloid cardiomyopathy can indirectly affect the central nervous system by inducing systemic hypoperfusion and increasing the risk of acute ischaemic stroke.
Domenico Mario Giamundo +3 more
wiley +1 more source
ABSTRACT Aims Elevated serum free light chain (FLC) and B‐cell activating factor (BAFF) levels have been reported to be associated with B‐cell activation and to serve as biomarkers reflecting disease severity in various diseases. However, limited investigation has been conducted in the context of chronic liver disease (CLD), and the aim of this study ...
Motoh Iwasa +8 more
wiley +1 more source
Monoclonal gammopathy with systemic amylodosis: an evaluation of diagnostic elements [PDF]
Monoclonal gammopathies result from an overproduction of a single abnormal clone of plasma cell or B lymphocyte that produce an immunologically homogenous immunoglobulin (Ig) commonly referred to as paraprotein or monoclonal (M) protein.
Chellappah Thambiah, Subashini +2 more
core
ABSTRACT Background Amyloidosis is a rare, multisystem disorder characterized by extracellular deposition of misfolded protein fibrils. Gastrointestinal (GI) amyloidosis is uncommon but under‐recognized due to nonspecific symptoms, but early diagnosis is critical to improve quality of life and prognosis.
Myo Jin Tang +3 more
wiley +1 more source

